



|                                      |     |            |  |   |  |         |     |     |                 |        |      |   |   |
|--------------------------------------|-----|------------|--|---|--|---------|-----|-----|-----------------|--------|------|---|---|
| 1<br>Preferred<br>Stock              | (3) | 05/07/2014 |  | C |  | 863,672 | (3) | (3) | Common<br>Stock | 42,336 | \$ 0 | 0 | D |
| 2<br>Series D-<br>Preferred<br>Stock | (4) | 05/07/2014 |  | C |  | 623,880 | (4) | (4) | Common<br>Stock | 30,582 | \$ 0 | 0 | D |

## Reporting Owners

| Reporting Owner Name / Address                                    | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| FCPR Biotechnology Fund<br>57 RUE DE RICHELIEU<br>PARIS, IO 75002 |               | X         |         |       |

## Signatures

|  |  |                     |
|--|--|---------------------|
| By: /s/ Jean-Yves Nothias, Director            |  | 05/08/2014          |
| <small>**Signature of Reporting Person</small> |  | <small>Date</small> |

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Upon closing of the Issuer's initial public offering, each share of Series B Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-3.536 basis, and had no expiration date.
- (2) Upon closing of the Issuer's initial public offering, each share of Series C Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-3.536 basis, and had no expiration date.
- (3) Upon closing of the Issuer's initial public offering, each share of Series D-1 Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-20.4 basis, and had no expiration date.
- (4) Upon closing of the Issuer's initial public offering, each share of Series D-2 Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-20.4 basis, and had no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.